Cihan Togrul
Cihan Togrul has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Umit Gorkem
Hitit University Faculty of Medicine, Department of Obstetrics and Gynecology, Çorum, Türkiye
8 shared publications - Emine Arslan
Clinic of Obstetrics and Gynecology, Başkent University İstanbul Hospital, Istanbul, Turkey
2 shared publications Tayfun Güngör
2 shared publications- Özgür Kan
Koru Ankara Hospital
2 shared publications Ahmet Yalınkaya
Department of Obstetrics and Gynecology, Dicle University, Diyarbakir, Turkey
1 shared publication- Ali Emre Tahaoglu
Department of Obstetrics and Gynecology, Memorial Dicle Hospital, Diyarbakır, Turkey
1 shared publication
Latest Publications
- Open Access
- 20 December 2023
- Published by Hitit University in Hitit Medical Journal
The Relationship Between Serum Growth Differentiation Factor-15 (GDF-15) Levels and Clinical Outcomes in Infertile Women Receiving In-vitro Fertilization Treatment
Objective: It has been reported in many studies that Growth Differentiation Factor-15 (GDF-15) has an important role in physiological or pathological processes. As there is no study in the current scientific literature examining the status of GDF-15 in infertility and its treatment outcomes, we aimed to investigate this. Material and methods: According to their ovarian reserve characteristics, 88 infertile women were divided into three groups: normal ovarian reserve (NOR), diminished ovarian reserve (DOR), and polycystic ovary syndrome (PCOS). Estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-mullerian hormone (AMH), and GDF-15 levels were measured in their serum. The antagonist protocol patients' total oocyte, meiosis II (MII) oocytes, embryo count, and clinical pregnancy rates were documented. Results: In terms of serum GDF-15 concentrations, there was no statistically significant difference among the mean values of the three study groups. The mean FSH level at baseline was substantially higher in the DOR group compared to the PCOS group. The median serum AMH levels of all three groups were found to be statistically different. The antagonist protocol patients' total oocytes, meiosis II (MII) oocytes, embryo count, and clinical pregnancy rates were documented. Conclusion: In the present study, a significant and strong correlation between serum GDF-15 level and consequent embryo number was detected. Thereby, serum GDF-15 level may be considered to be a biomarker for predicting IVF clinical outcomes.
- 20 December 2023
- Published by Hitit University in Hitit Medical Journal
Open AccessThe Relationship Between Serum Growth Differentiation Factor-15 (GDF-15) Levels and Clinical Outcomes in Infertile Women Receiving In-vitro Fertilization Treatment
Objective: It has been reported in many studies that Growth Differentiation Factor-15 (GDF-15) has an important role in physiological or pathological processes. As there is no study in the current scientific literature examining the status of GDF-15 in infertility and its treatment outcomes, we aimed to investigate this. Material and methods: According to their ovarian reserve characteristics, 88 infertile women were divided into three groups: normal ovarian reserve (NOR), diminished ovarian reserve (DOR), and polycystic ovary syndrome (PCOS). Estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-mullerian hormone (AMH), and GDF-15 levels were measured in their serum. The antagonist protocol patients' total oocyte, meiosis II (MII) oocytes, embryo count, and clinical pregnancy rates were documented. Results: In terms of serum GDF-15 concentrations, there was no statistically significant difference among the mean values of the three study groups. The mean FSH level at baseline was substantially higher in the DOR group compared to the PCOS group. The median serum AMH levels of all three groups were found to be statistically different. The antagonist protocol patients' total oocytes, meiosis II (MII) oocytes, embryo count, and clinical pregnancy rates were documented. Conclusion: In the present study, a significant and strong correlation between serum GDF-15 level and consequent embryo number was detected. Thereby, serum GDF-15 level may be considered to be a biomarker for predicting IVF clinical outcomes.
- Open Access
- 25 December 2020
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- Vol. 26 (3) , 179-183
Is There An Association Between Kisspeptin Levels And Gestational Diabetes Mellitus?
Objective: To find out the relationship of maternal serum levels of kisspeptin with gestational diabetes mellitus status.Study Design: A total of 158 pregnant women between 24 and 28 weeks of gestation were divided into two groups according to gestational diabetes mellitus status: (i) Pregnant women with gestational diabetes mellitus (gestational diabetes mellitus group, n=76) and (ii) Healthy pregnant women (control group, n=82). Maternal serum concentrations of kisspeptin, insulin, and homeostasis model assessment-insulin resistance were assessed.Results: In both groups, there were no difference in terms of age and gestational age (p=0.058 and p=0.820, respectively). The median of body mass indices of both groups at 24 to 28 weeks of gestation were statistically similar (p=0.062). The serum concentrations of kisspeptin did not demonstrate significant differences between the gestational diabetes mellitus and control groups (p=0.28). There was a significant difference in terms of serum level of insulin and homeostasis model assessment-insulin resistance between the gestational diabetes mellitus and control groups (p<0.001).Conclusion: No differences were found in serum kisspeptin levels between pregnant women with GDM and healthy pregnant women. Further prospective studies will be essential to elucidate the contribution of kisspeptin to gestational diabetes mellitus.
- 25 December 2020
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- Vol. 26 (3) , 179-183
Open AccessIs There An Association Between Kisspeptin Levels And Gestational Diabetes Mellitus?
Objective: To find out the relationship of maternal serum levels of kisspeptin with gestational diabetes mellitus status.Study Design: A total of 158 pregnant women between 24 and 28 weeks of gestation were divided into two groups according to gestational diabetes mellitus status: (i) Pregnant women with gestational diabetes mellitus (gestational diabetes mellitus group, n=76) and (ii) Healthy pregnant women (control group, n=82). Maternal serum concentrations of kisspeptin, insulin, and homeostasis model assessment-insulin resistance were assessed.Results: In both groups, there were no difference in terms of age and gestational age (p=0.058 and p=0.820, respectively). The median of body mass indices of both groups at 24 to 28 weeks of gestation were statistically similar (p=0.062). The serum concentrations of kisspeptin did not demonstrate significant differences between the gestational diabetes mellitus and control groups (p=0.28). There was a significant difference in terms of serum level of insulin and homeostasis model assessment-insulin resistance between the gestational diabetes mellitus and control groups (p<0.001).Conclusion: No differences were found in serum kisspeptin levels between pregnant women with GDM and healthy pregnant women. Further prospective studies will be essential to elucidate the contribution of kisspeptin to gestational diabetes mellitus.
- Open Access
- 2 December 2019
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- Vol. 25 (3) , 148-152
Is there a relationship between ovarian reserve and blood groups in infertile patients?
Objective: Evaluation of ovarian reserve in infertile patients had become an important concept in assisted reproductive techniques (ART) success work-up. Recent studies reported an association between blood type and ovarian reserve. Therefore, the aim of this study was to analyze the relationship between blood type and ovarian reserve in infertile patients.Study Design: In this retrospective, observational and single-center study, a total of 311 women who were applied for fertility seek between January 2018 and November 2018 were included. As a threshold of ovarian reserve, - serum follicle stimulating hormone levels (>10 mLU/mL) and antral follicle counts (≤5) at early follicular phase were taken to reflect diminished ovarian reserve (DOR). The main outcome was the association between blood types and ovarian reserve. Secondary outcomes were biochemical and clinical pregnancy rates.Results: There was no relationship between blood types and follicle stimulating hormone levels (FSH). Elevated FSH levels were associated with only age and antral follicle count. Similar to the results of ovarian reserve, biochemical and clinical pregnancy outcomes are not affected by blood groups and Rhesus factor.Conclusion: Patients' blood type did not have any impact on ovarian reserve. In addition, neither blood type nor rhesus factor have an effect on predicting pregnancy outcomes in ART patients.
- 2 December 2019
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- Vol. 25 (3) , 148-152
Open AccessIs there a relationship between ovarian reserve and blood groups in infertile patients?
Objective: Evaluation of ovarian reserve in infertile patients had become an important concept in assisted reproductive techniques (ART) success work-up. Recent studies reported an association between blood type and ovarian reserve. Therefore, the aim of this study was to analyze the relationship between blood type and ovarian reserve in infertile patients.Study Design: In this retrospective, observational and single-center study, a total of 311 women who were applied for fertility seek between January 2018 and November 2018 were included. As a threshold of ovarian reserve, - serum follicle stimulating hormone levels (>10 mLU/mL) and antral follicle counts (≤5) at early follicular phase were taken to reflect diminished ovarian reserve (DOR). The main outcome was the association between blood types and ovarian reserve. Secondary outcomes were biochemical and clinical pregnancy rates.Results: There was no relationship between blood types and follicle stimulating hormone levels (FSH). Elevated FSH levels were associated with only age and antral follicle count. Similar to the results of ovarian reserve, biochemical and clinical pregnancy outcomes are not affected by blood groups and Rhesus factor.Conclusion: Patients' blood type did not have any impact on ovarian reserve. In addition, neither blood type nor rhesus factor have an effect on predicting pregnancy outcomes in ART patients.
- 1 April 2019
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 33 (24) , 4159-4163
Relationship between elevated serum level of placental growth factor and status of gestational diabetes mellitus
Objective: As only limited and confusing evidence about serum placental growth factor (PlGF) level in gestational diabetes mellitus (GDM) exist in the known literature, the aim of this study was to evaluate the association of maternal serum PlGF level with GDM status. Methods: The pregnant women attending the Obstetrics Outpatient Unit of Hitit University Hospital were screened at 24 and 28 weeks of gestation for GDM according to the suggestions of the American College of Obstetricians and Gynecologists (ACOG). Concisely, all of the low-risk pregnant women were evaluated with a 50 g glucose challenge test (GCT). Women with serum glucose ≥140 mg/dL at 1 h after GCT were subjected to a 100 g oral glucose tolerance test (OGTT). According to the criteria of Carpenter and Coustan, the GDM diagnosis was confirmed. Consequently, a total of 158 pregnant women eligible for inclusion criteria were categorized into two main groups; 76 of the GDM group, 82 of the control group. The demographic characteristic and biochemical parameters of the study population including age, body mass index (BMI), gestational age were recorded at the second trimester. The assays for glucose, insulin, and PlGF were carried out. Results: The mean maternal age of control and GDM groups were 27.9 and 30.5 years, respectively. The parameters such as age, BMI, and gestational age were statistically similar in both groups (p>.05, for all). As expected, serum insulin level and homeostasis model assessment-insulin resistance (HOMA-IR) value were significantly elevated in women with GDM (p<.001, for both). Moreover, maternal PlGF concentration was found to be higher in the GDM group compared to the control group (p=.029). Pearson’s correlation analysis of PlGF with other study parameters revealed that there was a negative moderate and significant correlation in only control group (r= −0.416, p<.05). However, this correlation was not detected in the GDM group (r = 0.099, p>.05). None of the variables including maternal age, BMI, insulin, and HOMA-IR showed significant correlations in GDM and control groups. Conclusion: Our findings revealed that maternal serum PlGF level is increased in pregnant women complicated with GDM. Early identification of pregnant women who subsequently will pose GDM risk could improve the pregnancy outcomes.
- 1 April 2019
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 33 (24) , 4159-4163
Relationship between elevated serum level of placental growth factor and status of gestational diabetes mellitus
Objective: As only limited and confusing evidence about serum placental growth factor (PlGF) level in gestational diabetes mellitus (GDM) exist in the known literature, the aim of this study was to evaluate the association of maternal serum PlGF level with GDM status. Methods: The pregnant women attending the Obstetrics Outpatient Unit of Hitit University Hospital were screened at 24 and 28 weeks of gestation for GDM according to the suggestions of the American College of Obstetricians and Gynecologists (ACOG). Concisely, all of the low-risk pregnant women were evaluated with a 50 g glucose challenge test (GCT). Women with serum glucose ≥140 mg/dL at 1 h after GCT were subjected to a 100 g oral glucose tolerance test (OGTT). According to the criteria of Carpenter and Coustan, the GDM diagnosis was confirmed. Consequently, a total of 158 pregnant women eligible for inclusion criteria were categorized into two main groups; 76 of the GDM group, 82 of the control group. The demographic characteristic and biochemical parameters of the study population including age, body mass index (BMI), gestational age were recorded at the second trimester. The assays for glucose, insulin, and PlGF were carried out. Results: The mean maternal age of control and GDM groups were 27.9 and 30.5 years, respectively. The parameters such as age, BMI, and gestational age were statistically similar in both groups (p>.05, for all). As expected, serum insulin level and homeostasis model assessment-insulin resistance (HOMA-IR) value were significantly elevated in women with GDM (p<.001, for both). Moreover, maternal PlGF concentration was found to be higher in the GDM group compared to the control group (p=.029). Pearson’s correlation analysis of PlGF with other study parameters revealed that there was a negative moderate and significant correlation in only control group (r= −0.416, p<.05). However, this correlation was not detected in the GDM group (r = 0.099, p>.05). None of the variables including maternal age, BMI, insulin, and HOMA-IR showed significant correlations in GDM and control groups. Conclusion: Our findings revealed that maternal serum PlGF level is increased in pregnant women complicated with GDM. Early identification of pregnant women who subsequently will pose GDM risk could improve the pregnancy outcomes.
- 21 September 2017
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 34 (2) , 157-160
Is there a role for kisspeptin in pathogenesis of polycystic ovary syndrome?
Aim: To investigate association of kisspeptin levels in infertile women with different ovarian reserve patterns. Materials and methods: In this prospective cross-sectional study, 157 participants were recruited. The women were divided into three groups: (i) adequate ovarian reserve (AOR) (n = 57), (ii) high ovarian reserve (PCOS) (n = 60), (iii) diminished ovarian reserve (DOR) (n = 40). Weight, height, waist circumference (WC), hip circumference (HC), body mass index (BMI), waist/hip ratio (WHR) were measured. The blood samples were analyzed for estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), 17-hydroxy progesterone (17OHP), dehydroepiandrosterone sulfate (DHEAS), antimullerian hormone (AMH), kisspeptin measurements. Results: FSH concentration was higher and AMH concentration was lower in DOR group (p < .001, p < .001, respectively). The mean LH, TT and DHEAS levels were higher in PCOS group (p = .001, p < .00 and p = .003, respectively). The 17OHP level did not differ among the groups (p = .15). Women with PCOS possessed the highest kisspeptin level (p = .01). The kisspeptin level was negatively correlated with FSH level (r = −0.18, p = .02) and positively correlated with TT and DHEAS levels (r = 0.17, p = .02 and r = 0.23, p = .003, respectively). Conclusions: Women with PCOS had increased serum kisspeptin levels. Kisspeptin concentrations were negatively correlated with serum FSH and positively correlated with serum TT and DHEAS levels.
- 21 September 2017
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 34 (2) , 157-160
Is there a role for kisspeptin in pathogenesis of polycystic ovary syndrome?
Aim: To investigate association of kisspeptin levels in infertile women with different ovarian reserve patterns. Materials and methods: In this prospective cross-sectional study, 157 participants were recruited. The women were divided into three groups: (i) adequate ovarian reserve (AOR) (n = 57), (ii) high ovarian reserve (PCOS) (n = 60), (iii) diminished ovarian reserve (DOR) (n = 40). Weight, height, waist circumference (WC), hip circumference (HC), body mass index (BMI), waist/hip ratio (WHR) were measured. The blood samples were analyzed for estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), 17-hydroxy progesterone (17OHP), dehydroepiandrosterone sulfate (DHEAS), antimullerian hormone (AMH), kisspeptin measurements. Results: FSH concentration was higher and AMH concentration was lower in DOR group (p < .001, p < .001, respectively). The mean LH, TT and DHEAS levels were higher in PCOS group (p = .001, p < .00 and p = .003, respectively). The 17OHP level did not differ among the groups (p = .15). Women with PCOS possessed the highest kisspeptin level (p = .01). The kisspeptin level was negatively correlated with FSH level (r = −0.18, p = .02) and positively correlated with TT and DHEAS levels (r = 0.17, p = .02 and r = 0.23, p = .003, respectively). Conclusions: Women with PCOS had increased serum kisspeptin levels. Kisspeptin concentrations were negatively correlated with serum FSH and positively correlated with serum TT and DHEAS levels.
- Open Access
- 10 March 2017
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- p. 1-5
Bakri balloon placement effectively treats uterine atony and placenta previa
The aim of this study was to explore the success rates of Bakri balloon placement in patients with placenta previa and uterine atony. In addition, we compared bilateral internal iliac artery ligation (B-IIAL) and Bakri balloon placement in terms of their ability to inhibit haemorrhage in postpartum placenta previa patients. The hospital reports filed annually from 2010 to 2015 were reviewed. In total, 54 patients were evaluated: 42 patients with placenta previa and uterine atony were treated with Bakri balloons, and 12 placenta previa patients with postpartum haemorrhage underwent B-IIAL when medical treatment failed. The results showed that the success rates of Bakri balloon placement rate in placenta previa and uterine atony patients were 71.4% and 89.2%, respectively. The comparative analysis of placenta previa patients treated via Bakri balloon placement and B-IIAL showed that the requirements for packed red blood cell and fresh frozen plasma, pre- and post-partum haemoglobin levels, pre- and post-partum platelet counts, and hospitalization times differed significantly between the two groups (all p < 0.05). Bakri balloon tamponade could be considered an effective treatment for placenta previa and uterine atony. The technique is minimally invasive and can serve as a second-line treatment for patients with postpartum haemorrhage when medical procedures fail.
- 10 March 2017
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- p. 1-5
Open AccessBakri balloon placement effectively treats uterine atony and placenta previa
The aim of this study was to explore the success rates of Bakri balloon placement in patients with placenta previa and uterine atony. In addition, we compared bilateral internal iliac artery ligation (B-IIAL) and Bakri balloon placement in terms of their ability to inhibit haemorrhage in postpartum placenta previa patients. The hospital reports filed annually from 2010 to 2015 were reviewed. In total, 54 patients were evaluated: 42 patients with placenta previa and uterine atony were treated with Bakri balloons, and 12 placenta previa patients with postpartum haemorrhage underwent B-IIAL when medical treatment failed. The results showed that the success rates of Bakri balloon placement rate in placenta previa and uterine atony patients were 71.4% and 89.2%, respectively. The comparative analysis of placenta previa patients treated via Bakri balloon placement and B-IIAL showed that the requirements for packed red blood cell and fresh frozen plasma, pre- and post-partum haemoglobin levels, pre- and post-partum platelet counts, and hospitalization times differed significantly between the two groups (all p < 0.05). Bakri balloon tamponade could be considered an effective treatment for placenta previa and uterine atony. The technique is minimally invasive and can serve as a second-line treatment for patients with postpartum haemorrhage when medical procedures fail.
- 30 March 2016
- Vol. 82 (9) , 974-80
Preoperative anxiety may increase postcesarean delivery pain and analgesic consumption.
The aim of this study was to reveal the relationship between high level of prenatal anxiety and postoperative pain and/or analgesic consumption in women undergoing elective cesarean delivery under spinal anesthesia. Eighty women, aged between 18-45 years with minimum 37 week- gestation and received spinal anesthesia during elective cesarean delivery, were included into this observational cohort study. Prenatal anxiety was measured with state anxiety inventory, trait anxiety inventory and somatosensory amplification scale. Visual Analogue Scale (VAS) was used to quantify postoperative pain. Amount of analgesic consumed was recorded at 6th, 12th and 18th postoperative hours. State Anxiety Score was above the threshold level (>45) in 18 women (22.5%). No difference was found between women with and without high state anxiety scores except for significantly higher BMI values in high-score group (P=0.07). In multivariate analysis, high BMI at pregnancy (OR: 1.2, 95% CI; 1.0-1.5, P=0.02) and high State Anxiety Score (OR: 1.1, 95% CI; 1.0-1.2, P=0.01) emerged as independent predictors of higher mean pain scores (VAS >4 cm) within 18 hours after cesarean delivery. Also, high State Anxiety Score was found to be independently associated with higher pethidine consumption after cesarean delivery (OR: 1.1, 95% CI; 1.0-1.2, P=0.006). State anxiety has a negative effect on postcesarean pain whereas trait anxiety does not seem to produce such effect. The effect seems to be more profound in overweight women. Detection of anxiety level before elective cesarean delivery and therapeutic approach to pregnant women may be useful for postoperative pain control.
- 30 March 2016
- Vol. 82 (9) , 974-80
Preoperative anxiety may increase postcesarean delivery pain and analgesic consumption.
The aim of this study was to reveal the relationship between high level of prenatal anxiety and postoperative pain and/or analgesic consumption in women undergoing elective cesarean delivery under spinal anesthesia. Eighty women, aged between 18-45 years with minimum 37 week- gestation and received spinal anesthesia during elective cesarean delivery, were included into this observational cohort study. Prenatal anxiety was measured with state anxiety inventory, trait anxiety inventory and somatosensory amplification scale. Visual Analogue Scale (VAS) was used to quantify postoperative pain. Amount of analgesic consumed was recorded at 6th, 12th and 18th postoperative hours. State Anxiety Score was above the threshold level (>45) in 18 women (22.5%). No difference was found between women with and without high state anxiety scores except for significantly higher BMI values in high-score group (P=0.07). In multivariate analysis, high BMI at pregnancy (OR: 1.2, 95% CI; 1.0-1.5, P=0.02) and high State Anxiety Score (OR: 1.1, 95% CI; 1.0-1.2, P=0.01) emerged as independent predictors of higher mean pain scores (VAS >4 cm) within 18 hours after cesarean delivery. Also, high State Anxiety Score was found to be independently associated with higher pethidine consumption after cesarean delivery (OR: 1.1, 95% CI; 1.0-1.2, P=0.006). State anxiety has a negative effect on postcesarean pain whereas trait anxiety does not seem to produce such effect. The effect seems to be more profound in overweight women. Detection of anxiety level before elective cesarean delivery and therapeutic approach to pregnant women may be useful for postoperative pain control.
- 1 January 2016
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Case Reports
- Vol. 24 (4) , 319-322
Advanced Isthmic Ectopic Pregnancy Endangering the Life of the Mother: Case Report
- 1 January 2016
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Case Reports
- Vol. 24 (4) , 319-322
Advanced Isthmic Ectopic Pregnancy Endangering the Life of the Mother: Case Report
- Open Access
- 1 January 2016
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 7 (1)
Over kanserini taklit eden primer appendisiyal kanseri olgu sunumu
- 1 January 2016
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 7 (1)
Open AccessOver kanserini taklit eden primer appendisiyal kanseri olgu sunumu